par Shey, Robert Adamu;Ghogomu, Stephen M;Nebangwa, Neba Derrick;Shintouo, Cabirou Mounchili;Yaah, Ntang Emmaculate;Yengo, Bernis Neneyoh;Nongley, Nkemngo Francis;Esoh, Kevin Kum;Tchatchoua, Nelly Manuela Tatchou;Mbachick, Tekoh Terriss;Dede, Api Fon;Lemoge, Arnaud Azonpi;Ngwese, Roland Akwelle;Asa, Bertha Fru;Ayong, Lawrence;Njemini, Rose;Vanhamme, Luc ;Souopgui, Jacob
Référence Frontiers in Tropical Diseases, 3, 1046522
Publication Publié, 2022
Référence Frontiers in Tropical Diseases, 3, 1046522
Publication Publié, 2022
Article révisé par les pairs
Résumé : | Almost a decade ago, it was recognized that the global elimination of onchocerciasis by 2030 will not be feasible without, at least, an effective prophylactic and/or therapeutic vaccine to complement chemotherapy and vector control strategies. Recent advances in computational immunology (immunoinformatics) have seen the design of novel multi-epitope onchocerciasis vaccine candidates which are however yet to be evaluated in clinical settings. Still, continued research to increase the pool of vaccine candidates, and therefore the chance of success in a clinical trial remains imperative. Here, we designed a multi-epitope vaccine candidate by assembling peptides from 14 O. volvulus (Ov) proteins using an immunoinformatics approach. An initial 126 Ov proteins, retrieved from the Wormbase database, and at least 90% similar to orthologs in related nematode species of economic importance, were screened for localization, presence of transmembrane domain, and antigenicity using different web servers. From the 14 proteins retained after the screening, 26 MHC-1 and MHC-II (T-cell) epitopes, and linear B-lymphocytes epitopes were predicted and merged using suitable linkers. The Mycobacterium tuberculosis Resuscitation-promoting factor E (RPFE_MYCTU), which is an agonist of TLR4, was then added to the N-terminal of the vaccine candidate as a built-in adjuvant. Immune simulation analyses predicted strong B-cell and IFN-γ based immune responses which are necessary for protection against O. volvulus infection. Protein-protein docking and molecular dynamic simulation predicted stable interactions between the 3D structure of the vaccine candidate and human TLR4. These results show that the designed vaccine candidate has the potential to stimulate both humoral and cellular immune responses and should therefore be subject to further laboratory investigation. |